The BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) assay is a molecular screening test for detection of MRSA in nasal colonization. This assay coamplifies the extremity of staphylococcal chromosome cassette mec (SCCmec) and adjacent chromosomal DNA at the SCCmec insertion site. Increasing reports of novel SCCmec types and the diverse genetic backgrounds of MRSA strains prompted us to test the accuracy of the BD GeneOhm MRSA kit with 914 MRSA isolates with a variety of SCCmec types harbored in 21 genetic backgrounds, as determined by the multilocus sequence type (ST). The BD GeneOhm MRSA assay was performed on colony lysates; purified genomic DNA (0.2 pg/l and 0.2 ng/l) was tested to confirm negative results from lysates. Of 914 MRSA isolates tested, 911 tested positive (detection rate, 99.7%). The SCCmec types carried by assay-positive isolates were I, II, III, IV, V, V (5C2&5) , VI, and VIII and SCCmec composite islands with mec class A and ccr complexes 2 and 4. One of the assay-negative isolates had a communityassociated genotype: ST8, SCCmec type IV. However, this was an outlier among the 99.8% (434/435) ST8, SCCmec type IV-containing isolates that tested positive. The two other assay-negative isolates had a health care-associated genotype (ST5); both carried a distinct, uncommon, composite SCCmec type. In summary, the BD GeneOhm MRSA assay had a high rate of detection of MRSA isolates harboring common and uncommon SCCmec types from the United States and Taiwan.
The increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infection in the United States (16) has influenced many institutions and lawmakers to implement screening for MRSA colonization. In Illinois, screening for asymptomatic MRSA colonization has been mandated for all patients admitted to intensive care units (ICUs). The BD GeneOhm MRSA assay (BD Diagnostics GeneOhm, Québec City, Québec, Canada), approved for use for detection of MRSA colonization from nasal swabs, has been used by the University of Chicago Medical Center (UCMC) to identify patients who are colonized with MRSA upon admission to the ICU. However, since the initial validation of the assay (13) , few studies have been done to validate the assay against genetically diverse MRSA isolates (1, 11, 20, 24) . To date, no study has validated the BD GeneOhm MRSA assay with MRSA isolates circulating in the United States.
The BD GeneOhm MRSA assay uses a real-time PCR strategy (13) to detect the staphylococcal chromosome cassette mec (SCCmec) element. SCCmec harbors the mecA gene, which encodes a penicillin-binding protein (PBP 2a) with a low affinity for all available ␤-lactams. With rare exceptions, MRSA isolates carry the SCCmec integrated site specifically at the 3Ј end of the orfX gene in the chromosome. The primers and probes of the BD GeneOhm MRSA assay detect a proprietary sequence in the orfX gene adjacent to the SCCmec integration site and the SCCmec terminus, as described previously (13) . Since coagulase-negative staphylococcus species are often methicillin resistant and also carry SCCmec (12, 15, 19) , the species-specific primer in orfX ensures that the assay will not mistake methicillin-resistant coagulase-negative Staphylococcus species for MRSA. SCCmec elements are characterized by the mec class and ccr recombinase complex responsible for integration and excision of the element. They also have distinct inverted and direct repeats at the left and right termini (14) . Eight SCCmec types (types I to VIII) have been delineated on the basis of the class of mec (class A, B, C1, C2, or D) and ccr gene complexes (ccrAB or ccrC) that are present (14) . SCCmec types have been further stratified into subtypes due to variations in DNA sequence found in the 5Ј and 3Ј termini and the intervening regions between the ccr and mec gene complexes (14) . Adding to the repertoire are composite SCCmec elements that contain two different ccr complexes. Attesting to the presumed ability of SCCmec elements to transfer between strains, a given SCCmec type can be found in the genomes of a variety of S. aureus genetic backgrounds, as defined by several methods, including multilocus sequence typing (MLST), spa typing, and pulsed-field gel electrophoresis (PFGE) typing (4) . For instance, SCCmec type IV (SCCmec IV) elements with nearly identical DNA sequences have been found in MRSA strains MW2 (pulsotype USA400 and sequence type [ST] 1 [ST1]) (18) and FPR3757 (USA300 and ST8) (26) and the coagulasenegative species Staphylococcus epidermidis (9) .
Although the primer and probe sets used in designing the BD GeneOhm MRSA assay were previously validated with a worldwide collection of MRSA isolates, methicillin-susceptible S. aureus (MSSA) isolates, and coagulase-negative staphylococci (13), the SCCmec types and genetic backgrounds of the isolates were not known then. Moreover, increasing numbers of reports have documented DNA sequence variation among SCCmec elements (1-3, 5, 9, 14, 22) (20) have reported on isolates in their collections from Denmark, Finland, Switzerland, and Ireland, respectively, that were not detected by this assay, despite the presence of an SCCmec element. We therefore sought to assess the reliability of the BD GeneOhm MRSA assay in detecting MRSA isolates that had a variety of SCCmec types and genetic backgrounds that we obtained from the United States. MRSA isolates from Taiwan that had genotypes that differed from those in our collection were also included.
MATERIALS AND METHODS
MRSA strains. The BD GeneOhm MRSA assay was tested with 914 MRSA culture isolates. Nine hundred six of these were stored in our collection as part of ongoing surveillance of MRSA in the years spanning 1995 to 2006, as described previously (5) (6) (7) (8) (NARSA) . In addition, we included the SCCmec type VI typing strain from Herminia deLencastre from Portugal (0.1%). The MRSA isolates were obtained from a variety of sites of isolation. Of 688 isolates with a documented site of isolation, 33% were from skin or wounds, 20% were from abscesses, 16% were from the respiratory tract, 11% were from blood cultures, 9% were from nasal colonization, 3% were from bone or joint, 1% were from homografts, and 3% were from nonvascular devices (Foley or straight catheters [n ϭ 5], drainage from Jackson Pratt devices [n ϭ 2], wound drainage from gastrostomy tubes [n ϭ 2]). Two percent of isolates were from vascular indwelling devices, and 2% were from peritoneal or other body fluids.
Isolates were selected from a variety of molecular types, as described in Results (Table 1 ). All isolates were subjected to the Staphaurex latex agglutination test (Remel, Lenexa, KS) to confirm the species identification and mecA PCR to confirm methicillin resistance. Isolates were stored in skim milk (Difco, BD, Sparks, MD) at Ϫ80°C. Antimicrobial susceptibility profiles were determined using the Vitek2 automated testing system (bioMérieux, Durham, NC). Isolates were studied with the approval of the University of Chicago Institutional Review Board.
Molecular typing. Typing of SCCmec elements was performed by PCR using type-specific primers, as described previously (5) . SCCmec types I to VIII were assigned according to ccr complex and mec class, as specified by recently published guidelines for SCCmec nomenclature (14) . The name of SCCmec V T was recently changed to "SCCmec type V (5C2&5) " (14) . Control strains used for SCCmec typing, NCTC10442 (SCCmec I), N315 (SCCmec II), 85/2082 (SCCmec III), and WIS (SCCmec V), were kindly provided by Keiichi Hiramatsu and Teruyo Ito (Juntendo University, Japan). Strain MW2 (SCCmec type IV) was obtained from NARSA.
The genetic background of the isolates is reported as the ST, which was determined using MLST (10) . This technique involves determining the DNA sequences of 7 housekeeping genes and comparing them with those deposited in an international database (www.saureus.mlst.net) hosted at Imperial College. The ancestral lineage (clonal cluster [CC]) of each ST was determined by eBurst analysis performed on the MLST web browser. The PCR primers for amplifying mecA were 5Ј-CTTTGCTAGAGTAGCACTCG-3Ј and 5Ј-GCTAGCCATTCC TTTATCTTG-3Ј. The PCR primers for amplifying spa were 5Ј-TAAAGACGA TCCTTCGGTGAGC-3Ј (nucleotides [nts] 945 to 966; GenBank accession number EF455822) and 5Ј-CAGCAGTAGTGCCGTTTGCTT-3Ј (nts 1319 to 1339; GenBank accession number EF455822) and were used according to the assay conditions reported previously (21). Table 2 .
d Untypeable is defined as undetectable ccr genes or mec class using currently known typing primers.
e "Assay" refers to the BD GeneOhm MRSA assay. f ND, not determined. g slv, single-locus variant.
Performance of BD GeneOhm MRSA assay. Stored isolates were streaked onto tryptic soy agar (TSA) and incubated overnight at 37°C. To obtain DNA from crude cell lysates, several colonies from each plate were suspended in Tris (10 mM)-EDTA (0.5 mM), pH 8.0, to an optical density at 600 nm (OD 600 ) equal to a 0.5 McFarland standard (1 ϫ 10 8 CFU/ml). A 50-l aliquot of the cell suspension was transferred to a lysis tube supplied with the BD GeneOhm MRSA assay (version 3) kit and then processed according to the manufacturer's instructions. Briefly, the lysis tubes containing the cell suspension were vortexed for 5 min at high speed using a standard laboratory vortexing apparatus. To remove the cellular debris and unlysed cells, the samples were briefly centrifuged and heated at 95 Ϯ 2°C for 2 min. The lysed samples were kept on ice until use. A 2.8-l aliquot of each supernatant was added to 25 l of reconstituted master mix in a SmartCycler tube (Cepheid, Sunnyvale, CA), and the tube was centrifuged for 5 s. The real-time PCR amplification and detection of products were performed on a SmartCycler instrument using the BD GeneOhm MRSA assay protocol provided by the manufacturer. In addition to the positive and negative controls provided in the assay kit, a fresh lysate from an MSSA isolate (strain RN4220) was included as an external negative control in each assay.
When lysates tested negative, the MRSA isolates were further tested by isolating genomic DNA (gDNA) using a DNeasy blood and tissue kit (Qiagen Sciences, MD), as recommended by the manufacturer, except that lysostaphin (50 g/ml) was used in the resuspension buffer and the isolates were incubated at 37°C for 30 min. The concentration of genomic DNA was measured using a NanoDrop Technologies, Inc. , and 1.8 ϫ 10 2 copies of gDNA per reaction mixture, respectively. The lysates from each negative sample were tested for the presence of mecA. Since coagulase-negative species can also harbor mecA, isolates were confirmed to be S. aureus by PCR detection of spa, the S. aureusdefining gene encoding protein A.
RESULTS
MRSA sample subjected to BD GeneOhm MRSA assay. A sample of 914 cultured MRSA isolates was chosen for testing the BD GeneOhm MRSA assay. This sample included every combination of SCCmec type and genetic background that was available in our collection. The percentage of each SCCmec type and the variety of genetic backgrounds (according to ST) harboring each SCCmec type that were tested with the BD GeneOhm MRSA assay are shown in Table 1 . This consisted of 21 STs distributed over 8 SCCmec types, a nontypeable isolate, and composite SCCmec types. For example, there were isolates from 9 different STs that carried SCCmec type II and isolates from 15 different STs that carried SCCmec type IV. Among the 914 MRSA isolates that we tested, there were 8 different previously characterized SCCmec types [SCCmec types I, II, III, IV, V, V (5C2&5) , VI, and VIII] and 6 SCCmec types presumed to be composite islands since more than one ccr complex was detected. One isolate was defined as untypeable since the primers used to detect ccr complex allotypes 1 to 5 did not amplify a product. The two most prevalent SCCmec types were types IV (69.8%) and II (27%). Eighty-one percent of the SCCmec type II-containing isolates were ST5, and 68% of the SCCmec type IV-containing isolates were ST8. The predominance of these types reflects the fact that they are the most prevalent SCCmec types present among community-associated (CA) MRSA and health care-associated (HA) MRSA strains in the United States (7, 17) . SCCmec type VIII contains ccr complex 4 and mec class A (28). The two SCCmec type V-containing isolates were from patients at UCMC; each had an unusual ST for the UCMC geographic area (ST72 and ST87). The two SCCmec type VIII-containing isolates were also from two patients at UCMC and had ST5 and ST8 genetic backgrounds. Isolates from Taiwan included the isolate containing SCCmec V T (5), which was recently reclassified V (5C2&5) (14) .
The characteristics of the six strains presumed to contain composite SCCmec elements are shown in Table 2 . There were three distinct types of the ccr complex and mec class combinations: four of the six tested positive for ccr complexes 2 and 4 with mec class A, one had ccr complexes 2 and 5 with mec class A, and one had ccr complexes 2 and 4 with mec class B. No epidemiologic link between the four isolates with the same ccr and mec class profile (ccr complexes 2 and 4 with mec class A) could be established with respect to date or place of isolation.
Results obtained with BD GeneOhm MRSA assay. Lysates from 914 MRSA isolates were subjected to the BD GeneOhm MRSA assay; 99.7% tested positive ( Table 1 ). The percent from each SCCmec type testing positive, stratified by ST, is shown in Table 1 . All but one SCCmec type IV-containing isolate and all isolates containing SCCmec types I, II, III, V, V (5C2&5), VI, and VIII tested positive. Additionally, the untypeable isolate and 4/6 (67%) isolates with probable composite SCCmec elements (isolates 788, 1205, 2411, and 2754) tested positive in the assay; all four had ccr complexes 2 and 4 and mec class A (Table 2) .
BD GeneOhm MRSA assay-negative MRSA isolates. All three assay-negative isolates were obtained from patients at UCMC. Features of these three isolates (isolates 2582, 2790, and 2915) are shown in Table 3 . The lysates from all three isolates were mecA and spa positive by PCR, confirming the MRSA genotype and the DNA integrity of the lysates. The assay was repeated with fresh lysates of these three assaynegative isolates at least 6 times. For one isolate (isolate 2790), 6 of 7 (86%) of the replicate assays tested negative; on one 
a Although SCCmec types III and V (5C2&5) are considered composite islands, data for the strain containing these elements are not included here but are shown in Table 1 .
b Ery, erythromycin; Cli, clindamycin; Cip, ciprofloxacin; Gnt, gentamicin; Oxa, oxacillin; Rif, rifampin; Van, vancomycin; R, resistant; S, susceptible; I, intermediate.
occasion, this isolate tested positive. When the SCCmec types and STs were evaluated, it is clear that the isolates were unrelated. Two of the three assay-negative isolates (isolates 2915 and 2582) had a probable composite SCCmec type (Table 2) , and one isolate (isolate 2790) carried SCCmec type IV (Table 2) . Although the two isolates with probable composite SCCmec elements were ST5, the compositions of their SCCmec elements differed from each other; whereas isolate 2915 contained ccr complexes 2 and 4 and mec class B, isolate 2582 carried ccr complexes 2 and 5 and mec class A (Table 2) . Although composite SCCmec types comprised 6/914 (0.7%) isolates in the total sample, 33% (2 of 6) of the isolates with composite elements (0.2% of all MRSA isolates tested) tested negative. This difference in detection of MRSA between isolates with composite and noncomposite elements was significant (P Ͻ 0.001, Fisher's exact test). This suggests that composite SCCmec types are more likely to test negative in the BD GeneOhm MRSA assay. To substantiate that the negative assay results obtained using colony lysates were due to the DNA sequence of the isolates and were not an artifact of the lysate preparation, purified gDNA was assayed using concentrations of 10 ng/l, 0.2 ng/l, 2 pg/l, and 0.2 pg/l. The result was consistently negative for MSSA control strain RN4220 and the three assay-negative MRSA isolates when DNA concentrations spanning from 0.2 pg/l to 0.2 ng/l were used. However, with 10 ng/l of gDNA, a false-positive result was consistently obtained using gDNA from the MSSA strain and the three MRSA assay-negative strains. Thus, to avoid false-positive results, gDNA concentrations between 0.2 ng/l and 0.2 pg/l were evaluated in this study.
DISCUSSION
Molecular screening tests have the advantage of rapidly identifying MRSA carriage prior to admission into health care institutions. The BD GeneOhm MRSA assay is one such assay in widespread use in the United States, despite the lack of reported data that validate the reliability of the test for detection of circulating strains of MRSA. In our sample of 914 culture-proven MRSA isolates, of which 96% were from the United States, we found that the BD GeneOhm MRSA assay correctly identified a variety of MRSA strains with different genotypes and SCCmec types with an overall detection rate of 99.7% (99.6% among the U.S. isolates). Three MRSA isolates (0.3%), all from our medical center, tested negative with the assay, despite the fact that they were MRSA by Vitek testing and mecA PCR. The assay detected isolates from a wide variety of SCCmec types [types I, II, III, IV, V, V (5C2&5) , VI, and VIII, composite SCCmec types, and an untypeable isolate]. Not included in our strain collection was any isolate containing ccr complex 5 and mec class C1 (originally described by Berglund et al. from Sweden [2] and named SCCmec VII according to the revised nomenclature [14] ). However, the prototype isolate from Sweden containing SCCmec type VII tested positive with the BD GeneOhm assay when it was performed by the manufacturer (BD Diagnostics, Québec City, Québec, Canada). Although a limitation of our study is that most of the isolates studied were ST8 and ST5 isolates that carried type IV and II SCCmec, respectively, the diversity of our sample was enhanced by including every isolate with an unusual sporadic and singleton genotype that we identified during prospective molecular surveillance of culture-proven MRSA isolates. A more diverse collection would be difficult to find since the genotypic distribution of isolates that are naturally circulating in the United States is limited to primarily SCCmec IV and SCCmec II in ST8 and ST5 genetic backgrounds, respectively (7, 25) . In fact, compared with similar studies that tested the performance of the BD GeneOhm MRSA assay on MRSA isolates (1, 11, 20, 24) , our study is the largest performed to date and the only study performed in the United States.
The SCCmec types of the three BD GeneOhm MRSA assaynegative index isolates were distinct from each other, and therefore, the isolates do not represent a single clone. Two of the three assay-negative isolates had different composite SCCmec elements, but they both had the genetic background ST5, which is associated with HA MRSA in the United States. The third negative isolate has genetic markers associated with CA MRSA; it carries SCCmec type IV in an ST8 genetic background. Thus, a BD GeneOhm MRSA-negative result is not restricted to isolates with an HA or CA MRSA genotype. Moreover, these data show that even a common SCCmec type (type IV) is capable of evolving polymorphisms that render it undetectable by this assay.
The failure to detect three isolates with the BD GeneOhm MRSA assay can most likely be explained by polymorphisms occurring in the SCCmec extremity of these isolates that rendered the primers or probe unable to hybridize to the target DNA. It is also possible that polymorphisms in orfX were responsible. In Copenhagen, Denmark, a high false-negative rate (12.6%) (1) was reported for the BD GeneOhm MRSA assay; an MRSA clone with genetic background belonging to ST8 and spa type t024 carried an SCCmec extremity sequence that was not recognized by the primers supplied in the kit. A region-specific assay which greatly decreased the incidence of false-negative results was designed and implemented (1). In (27) or integration of SCC elements that lack mecA (23) could result in detection of an SCC cassette in MSSA isolates using the BD GeneOhm assay.
In conclusion, in contrast to the situation in Denmark and Finland, the BD GeneOhm MRSA assay detected a high percentage (99.7%) of MRSA genotypes with various SCCmec types obtained from various regions in the United States and Taiwan. DNA sequence analysis of the extremities of SCCmec elements of our assay-negative isolates is ongoing and will likely provide insight into the basis of the assay-negative results.
